Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: Comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2090-2096

  Ueda, Masashi ^a,b   Kudo, Takashi ^b   Mutou, Yasuko ^c   Umeda, Izumi Ogihara ^c   Miyano, Azusa ^b   Ogawa, Kei ^b   Ono, Masahiro ^b   Fujii, Hirofumi ^c   Kizaka Kondoh, Shinae ^d   Hiraoka, Masahiro ^b   Saji, Hideo ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; IODINATED CONTRAST MEDIUM; IPOS I 125; PIMONIDAZOLE; UNCLASSIFIED DRUG; 3 (IODOBENZOYL)NORBIOTINAMIDE PTD ODD SAV FUSION PROTEIN; 3-(IODOBENZOYL)NORBIOTINAMIDE-PTD-ODD-SAV FUSION PROTEIN; BIOTIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HIF1A PROTEIN, MOUSE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITROIMIDAZOLE DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIOACCUMULATION; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; EX VIVO STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERMETHOD COMPARISON; MACROMOLECULE; METABOLITE; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; X RAY; ANIMAL; C3H MOUSE; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; METHODOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BIOTIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IODINE RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOPLASM PROTEINS; NITROIMIDAZOLES; RADIOPHARMACEUTICALS; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80055011150     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02057.x     Document Type: Article

References (40)

1. Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci 2009; 100: 1366-73.
2. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
4. Schwartz DL, Powis G, Thitai-Kumar A et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009; 8: 947-58.
5. Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev 2009; 61: 623-32.
6. Serganova I, Doubrovin M, Vider J et al. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 2004; 64: 6101-8.
7. Lecomte R. Novel detector technology for clinical PET. Eur J Nucl Med Mol Imaging 2009; 36 (Suppl 1): S69-85.
8. Lewellen TK. Recent developments in PET detector technology. Phys Med Biol 2008; 53: R287-317.
9. Riemann B, Schafers KP, Schober O, Schafers M. Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging 2008; 52: 215-21.
10. Rowland DJ, Cherry SR. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 2008; 38: 209-22.
11. 2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4.
12. Choi HJ, Song BJ, Gong YD, Gwak WJ, Soh Y. Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2. Br J Pharmacol 2008; 154: 114-25.
13. Kizaka-Kondoh S, Itasaka S, Zeng L et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 2009; 15: 3433-41.
14. Kudo T, Ueda M, Kuge Y et al. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med 2009; 50: 942-9.
15. Ueda M, Kudo T, Kuge Y et al. Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1alpha. Eur J Nucl Med Mol Imaging 2010; 37: 1566-74.
16. Ueda M, Iida Y, Tominaga A et al. Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects. Br J Pharmacol 2010; 159: 1201-10.
17. Temma T, Ogawa Y, Kuge Y et al. Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model. J Nucl Med 2010; 51: 1979-86.
18. Kudo T, Ueda M, Konishi H et al. PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel (18)F-labeled biotin derivative. Mol Imaging Biol 2010; [Epub ahead of print].
19. Motta-Hennessy C, Sharkey RM, Goldenberg DM. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 1990; 31: 1510-9.
20. 18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36: 1565-73.
21. Dunphy MP, Lewis JS. Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 2009; 50 (Suppl 1): 106S-21S.
22. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49 (Suppl 2): 129S-48S.
23. 2 tension. Am J Physiol 1996; 271: C1172-80.
24. Yeom CJ, Chung JK, Kang JH et al. Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. J Nucl Med 2008; 49: 1489-97.
25. He F, Deng X, Wen B et al. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res 2008; 68: 8597-606.
26. Carlin S, Pugachev A, Sun X et al. In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nucl Med Biol 2009; 36: 821-31.
27. Harada H, Kizaka-Kondoh S, Itasaka S et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007; 360: 791-6.
28. Moroz E, Carlin S, Dyomina K et al. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 2009; 4: e5077.
29. Kuchimaru T, Kadonosono T, Tanaka S, Ushiki T, Hiraoka M, Kizaka-Kondoh S. In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system. PLoS One 2010; 5: e15736.
30. Grassi R, Cavaliere C, Cozzolino S et al. Small animal imaging facility: new perspectives for the radiologist. Radiol Med 2009; 114: 152-67.
31. Pissarek M, Meyer-Kirchrath J, Hohlfeld T et al. Targeting murine heart and brain: visualisation conditions for multi-pinhole SPECT with (99m)Tc- and (123)I-labelled probes. Eur J Nucl Med Mol Imaging 2009; 36: 1495-509.
32. van der Have F, Vastenhouw B, Ramakers RM et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med 2009; 50: 599-605.
33. Lehmann S, Stiehl DP, Honer M et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A 2009; 106: 14004-9.
34. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007; 67: 7646-53.
35. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 2005; 65: 7259-66.
36. Madani F, Lindberg S, Langel U, Futaki S, Graslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011; 2011: 414729.
37. Nakase I, Takeuchi T, Tanaka G, Futaki S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Deliv Rev 2008; 60: 598-607.
38. Hsieh CH, Kuo JW, Lee YJ, Chang CW, Gelovani JG, Liu RS. Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice. J Nucl Med 2009; 50: 2049-57.
39. Wen B, Burgman P, Zanzonico P et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 2004; 31: 1530-8.
40. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003; 94: 1021-8.